What is InVitroCare?
InVitroCare Inc. is a key provider of advanced assisted reproductive technology (ART) media and andrology products. Their offerings include a complete line of IUI products and equipment for efficient sperm isolation in medical settings, alongside a broad spectrum of andrology supplies for sperm preparation and cryopreservation. The company also manufactures embryo culture media and ICSI reagents. All products are developed and produced in FDA-registered facilities, adhering to stringent quality management systems including QMS, GAMP5, and ISO 13485 standards. InVitroCare primarily serves medical professionals and fertility clinics that require dependable reproductive technology solutions.
How much funding has InVitroCare raised?
InVitroCare has raised a total of $18K across 1 funding round:
Debt
$18K
Debt (2021): $18K with participation from PPP
Key Investors in InVitroCare
PPP
Public-Private Partnership
What's next for InVitroCare?
With the recent influx of moderate growth capital, InVitroCare is strategically positioned for its next phase of expansion. The company's commitment to high-quality, FDA-compliant manufacturing suggests a focus on enhancing production capabilities and potentially broadening its product portfolio. Future developments may include deeper penetration into existing markets and exploration of new geographical regions. The company's Series A/B growth stage funding context implies an emphasis on solidifying its market position and driving innovation in the competitive fertility and reproductive health sector.
See full InVitroCare company page
